Anasuya Patil
Research Subjects
Research Interests
Anasuya Patil has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Gaurav Tiwari
PSIT-Pranveer Singh Institute of Technology (Pharmacy), Kalpi Road, Bhauti, Kanpur-208020, India
2 shared publications - Hemanth G.
Department of Pharmaceutics, KLE College of Pharmacy, Rajajinagar, Bengaluru, India
2 shared publications - Anjaneyulu Vinukonda
Strides Pharma Inc., USA
1 shared publication - Ankur Agrawal
School of Pharmacy, Jai Institute of Pharmaceutical Sciences and Research, Gwalior, MP, India
1 shared publication - Bhaveshkumar A. Patel
Frontage Laboratories, Inc
1 shared publication - Dhruv Dev
Department of Pharmacy, Shivalik College of Pharmacy Nangal
1 shared publication
Latest Publications
- 7 March 2025
- Published by Sciencedomain International in Asian Journal of Research in Medical and Pharmaceutical Sciences
- Vol. 14 (2) , 129-141
Optimized Nanosponges for Topical Delivery of Posaconazole: A Promising Approach for Enhanced Antifungal Therapy
Aim: To enhance the topical delivery of posaconazole (PCZ) through the development of a nanosponge-based hydrogel system. Objective: To formulate and evaluate a Carbopol 934-based hydrogel containing optimized nanosponge (F6) for improved drug encapsulation, sustained release, and antifungal efficacy. Methods: The optimized nanosponge formulation (F6) was incorporated into a Carbopol 934 hydrogel. The resulting system was characterized using Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Physicochemical evaluations including pH, viscosity, and in vitro drug release were performed. The results were compared with a hydrogel formulation containing pure PCZ. Results: FTIR and DSC confirmed successful encapsulation of PCZ within the nanosponge matrix without chemical incompatibility. SEM analysis showed uniform nanosponge distribution. The nanosponge-loaded hydrogel exhibited suitable pH and viscosity for topical application and demonstrated significantly improved sustained drug release compared to the pure PCZ hydrogel. Conclusion: The nanosponge-based hydrogel system offers a promising approach for enhancing the topical delivery of PCZ. It showed improved drug retention, reduced dosing frequency, and potential for enhanced patient compliance, making it a suitable candidate for treating fungal skin infections.
- 7 March 2025
- Published by Sciencedomain International in Asian Journal of Research in Medical and Pharmaceutical Sciences
- Vol. 14 (2) , 129-141
Optimized Nanosponges for Topical Delivery of Posaconazole: A Promising Approach for Enhanced Antifungal Therapy
Aim: To enhance the topical delivery of posaconazole (PCZ) through the development of a nanosponge-based hydrogel system. Objective: To formulate and evaluate a Carbopol 934-based hydrogel containing optimized nanosponge (F6) for improved drug encapsulation, sustained release, and antifungal efficacy. Methods: The optimized nanosponge formulation (F6) was incorporated into a Carbopol 934 hydrogel. The resulting system was characterized using Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Physicochemical evaluations including pH, viscosity, and in vitro drug release were performed. The results were compared with a hydrogel formulation containing pure PCZ. Results: FTIR and DSC confirmed successful encapsulation of PCZ within the nanosponge matrix without chemical incompatibility. SEM analysis showed uniform nanosponge distribution. The nanosponge-loaded hydrogel exhibited suitable pH and viscosity for topical application and demonstrated significantly improved sustained drug release compared to the pure PCZ hydrogel. Conclusion: The nanosponge-based hydrogel system offers a promising approach for enhancing the topical delivery of PCZ. It showed improved drug retention, reduced dosing frequency, and potential for enhanced patient compliance, making it a suitable candidate for treating fungal skin infections.
- Open Access
- 7 January 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 334-343
FORMULATION AND EVALUATION OF ECONAZOLE NITRATE NANOEMULSION FOR TOPICAL OCULAR ADMINISTRATION
Objective: The study aimed to use cold homogenization to create an Econazole Nitrate (ECN) nano-emulsion formulation. Methods: Different ratios of surfactants (polypropylene 188 and Tween 80) and co-surfactants (ethanol) were used to create eight formulations. Out of them, compositions ECN1, ECN4, ECN5, and ECN7 were chosen due to initial research demonstrating encouraging outcomes. Dissolution studies evaluated droplet size, shape, drug content, and in vitro drug release characteristics. A comparative analysis was conducted to assess the improvement in medication release rates compared to pure drug formulations. Results: ECN5, which attained an 89.43% drug release rate after 360 min, demonstrated the greatest medication release rate among the chosen formulations (ECN1, ECN4, ECN5, and ECN7). The improved formulations showed consistent spherical forms with droplet diameters ranging from 114 nm to 214.87 nm. Based on these findings, it appears that the nano-emulsion formulation successfully raises econazole nitrate's solubility, which is important because of its poor solubility in ocular administration applications. Conclusion: The study used cold homogenization to effectively generate and optimize ECN nano-emulsion formulations. The most promising features of formulation ECN5, such as consistent droplet size distribution and dramatically improved drug release rates, were displayed. These results demonstrate the potential of nano-emulsions to enhance econazole nitrate's solubility and delivery effectiveness, especially for ocular applications.
- 7 January 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 334-343
Open AccessFORMULATION AND EVALUATION OF ECONAZOLE NITRATE NANOEMULSION FOR TOPICAL OCULAR ADMINISTRATION
Objective: The study aimed to use cold homogenization to create an Econazole Nitrate (ECN) nano-emulsion formulation. Methods: Different ratios of surfactants (polypropylene 188 and Tween 80) and co-surfactants (ethanol) were used to create eight formulations. Out of them, compositions ECN1, ECN4, ECN5, and ECN7 were chosen due to initial research demonstrating encouraging outcomes. Dissolution studies evaluated droplet size, shape, drug content, and in vitro drug release characteristics. A comparative analysis was conducted to assess the improvement in medication release rates compared to pure drug formulations. Results: ECN5, which attained an 89.43% drug release rate after 360 min, demonstrated the greatest medication release rate among the chosen formulations (ECN1, ECN4, ECN5, and ECN7). The improved formulations showed consistent spherical forms with droplet diameters ranging from 114 nm to 214.87 nm. Based on these findings, it appears that the nano-emulsion formulation successfully raises econazole nitrate's solubility, which is important because of its poor solubility in ocular administration applications. Conclusion: The study used cold homogenization to effectively generate and optimize ECN nano-emulsion formulations. The most promising features of formulation ECN5, such as consistent droplet size distribution and dramatically improved drug release rates, were displayed. These results demonstrate the potential of nano-emulsions to enhance econazole nitrate's solubility and delivery effectiveness, especially for ocular applications.
- 23 November 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (7) , 817-842
Biofunctionalized polymeric nanoparticles for the enhanced delivery of erlotinib in cancer therapy
- 23 November 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (7) , 817-842
Biofunctionalized polymeric nanoparticles for the enhanced delivery of erlotinib in cancer therapy
- 19 November 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (6) , 756-778
“Development, optimization, and characterization of Eudragit-based nanoparticles for Dasatinib delivery”
This study focused on developing and evaluating dasatinib-loaded nanoparticles (DST-NPs) using Eudragit L100 as a polymer matrix for enhanced breast cancer treatment. The optimized formulation exhibited a particle size of 202.1 ± 5.7 nm, a zeta potential of -18 ± 1.01 mV, and an entrapment efficiency of 93.11 ± 0.2%. In-vitro release studies demonstrated sustained drug release from DST-NPs, following Fickian diffusion. Pharmacokinetic studies in rats revealed higher Cmax and AUC0-t for DST-NPs compared to pure DST, indicating improved bioavailability. Tissue distribution studies showed enhanced targeting of DST-NPs, with higher concentrations in the liver and spleen. In vivo efficacy in a DMBA-induced mammary carcinoma model demonstrated that DST-NPs significantly reduced tumor volume, maintained stable body weight, and improved survival rates compared to pure DST. Hematologic analysis indicated a favorable blood profile with DST-NPs, and histopathological examinations confirmed the restoration of normal mammary gland and liver architecture. MTT assays showed higher cytotoxicity of DST-NPs against MCF-7, MDA-MB231, and 4T1 cell lines, with lower IC50 values than pure DST. Stability studies indicated that DST-NPs maintained their properties over six months at various storage conditions. These findings highlight the potential of DST-NPs as an effective nanocarrier system for cancer therapy.
- 19 November 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (6) , 756-778
“Development, optimization, and characterization of Eudragit-based nanoparticles for Dasatinib delivery”
This study focused on developing and evaluating dasatinib-loaded nanoparticles (DST-NPs) using Eudragit L100 as a polymer matrix for enhanced breast cancer treatment. The optimized formulation exhibited a particle size of 202.1 ± 5.7 nm, a zeta potential of -18 ± 1.01 mV, and an entrapment efficiency of 93.11 ± 0.2%. In-vitro release studies demonstrated sustained drug release from DST-NPs, following Fickian diffusion. Pharmacokinetic studies in rats revealed higher Cmax and AUC0-t for DST-NPs compared to pure DST, indicating improved bioavailability. Tissue distribution studies showed enhanced targeting of DST-NPs, with higher concentrations in the liver and spleen. In vivo efficacy in a DMBA-induced mammary carcinoma model demonstrated that DST-NPs significantly reduced tumor volume, maintained stable body weight, and improved survival rates compared to pure DST. Hematologic analysis indicated a favorable blood profile with DST-NPs, and histopathological examinations confirmed the restoration of normal mammary gland and liver architecture. MTT assays showed higher cytotoxicity of DST-NPs against MCF-7, MDA-MB231, and 4T1 cell lines, with lower IC50 values than pure DST. Stability studies indicated that DST-NPs maintained their properties over six months at various storage conditions. These findings highlight the potential of DST-NPs as an effective nanocarrier system for cancer therapy.
- 10 November 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (6) , 711-742
Preparation, optimization, and evaluation of ligand-tethered atovaquone-proguanil-loaded nanoparticles for malaria treatment
- 10 November 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (6) , 711-742
Preparation, optimization, and evaluation of ligand-tethered atovaquone-proguanil-loaded nanoparticles for malaria treatment
- 18 June 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 35 (13) , 2068-2089
Design, optimization, and evaluation of methotrexate loaded and albumin coated polymeric nanoparticles
Methotrexate is a potent anticancer drug whose strong efflux is facilitated by the brain's efflux transporter. As an efflux transporter blocker, albumin increased the drug's concentration in the brain. Methotrexate-loaded nanoparticles were produced by evaporating the emulsification fluid. Improvements and analyses were made to the following aspects of the generated nanoparticles: size, polydispersity, zeta potential, entrapment efficiency, percentage yield, scanning electron microscopy, in vitro drug release studies, and sterilization. The particle size was determined to be in the nano range, and homogeneity of particle size was suggested by a low polydispersity index result. Particle diameters of 168 nm were observed in the F5 preparation, and zeta potential values of -1.5 mV suggested that the preparation produced adequate repulsive interactions between the nanoparticles. Albumin and dopamine HCl were employed to coat the methotrexate-loaded nanoparticles to guarantee that the brain received an adequate amount of them. The homogeneity of albumin coated nanoparticles was demonstrated by the low% PDI values of 0.129 and 0.122 for albumin coated nanoparticles (MNPs-Alb) and polymerized dopamine HCl and albumin coated nanoparticles (MNPs-PMD-Alb), respectively. After 48 h of incubation, the cell viability measured at the same drug concentration (5 mg) decreased for the F5, albumin coated nanoparticles, polymerized dopamine HCl coated nanoparticles, and polymerized dopamine HCl and albumin coated nanoparticles, respectively. Our primary findings demonstrate that the albumin nanoparticles containing methotrexate are designed to deliver the drug gradually. With minimal cytotoxicity, the intended preparation might give the brain an appropriate dosage of methotrexate.
- 18 June 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 35 (13) , 2068-2089
Design, optimization, and evaluation of methotrexate loaded and albumin coated polymeric nanoparticles
Methotrexate is a potent anticancer drug whose strong efflux is facilitated by the brain's efflux transporter. As an efflux transporter blocker, albumin increased the drug's concentration in the brain. Methotrexate-loaded nanoparticles were produced by evaporating the emulsification fluid. Improvements and analyses were made to the following aspects of the generated nanoparticles: size, polydispersity, zeta potential, entrapment efficiency, percentage yield, scanning electron microscopy, in vitro drug release studies, and sterilization. The particle size was determined to be in the nano range, and homogeneity of particle size was suggested by a low polydispersity index result. Particle diameters of 168 nm were observed in the F5 preparation, and zeta potential values of -1.5 mV suggested that the preparation produced adequate repulsive interactions between the nanoparticles. Albumin and dopamine HCl were employed to coat the methotrexate-loaded nanoparticles to guarantee that the brain received an adequate amount of them. The homogeneity of albumin coated nanoparticles was demonstrated by the low% PDI values of 0.129 and 0.122 for albumin coated nanoparticles (MNPs-Alb) and polymerized dopamine HCl and albumin coated nanoparticles (MNPs-PMD-Alb), respectively. After 48 h of incubation, the cell viability measured at the same drug concentration (5 mg) decreased for the F5, albumin coated nanoparticles, polymerized dopamine HCl coated nanoparticles, and polymerized dopamine HCl and albumin coated nanoparticles, respectively. Our primary findings demonstrate that the albumin nanoparticles containing methotrexate are designed to deliver the drug gradually. With minimal cytotoxicity, the intended preparation might give the brain an appropriate dosage of methotrexate.
- Open Access
- 7 November 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 90-97
FORMULATION AND EVALUATION OF NANOPARTICLE DRUG DELIVERY SYSTEM FOR TREATMENT OF HYPERTENSION
Objective: The aim of the current research is to formulate and evaluate Trandolapril loaded solid lipid nanoparticles (SLNs) for the management of high blood pressure. Methods: SLNs were formulated using Glyceryl monostearate and poloxamer 188 by hot homogenisation and ultrasonication method. Different concentrations of lipid and surfactant were used for the preparation adopting 32 full factorial design. The prepared formulations were initially evaluated for particle size, PDI, zeta potential and entrapment efficiency to obtain the optimised formulation. Results: The optimised formulation TF 6 reported the particle size of 212.6±5.39 nm and entrapment efficiency of 91.02±0.57%; this was further characterised for FT-IR, DSC and scanning electron microscopy. The in vitro release of drug for the prepared formulations was performed for 24 h and the optimised formulation showed better-controlled drug release compared to other formulations. Conclusion: The pure Trandolapril solution was collated with the optimised formulation TF 6 and the result concluded that the formulation showed controlled drug release compared to pure drug. This study proves that Trandolapril SLNs can be prepared for increasing the release of drug for prolonged period.
- 7 November 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 90-97
Open AccessFORMULATION AND EVALUATION OF NANOPARTICLE DRUG DELIVERY SYSTEM FOR TREATMENT OF HYPERTENSION
Objective: The aim of the current research is to formulate and evaluate Trandolapril loaded solid lipid nanoparticles (SLNs) for the management of high blood pressure. Methods: SLNs were formulated using Glyceryl monostearate and poloxamer 188 by hot homogenisation and ultrasonication method. Different concentrations of lipid and surfactant were used for the preparation adopting 32 full factorial design. The prepared formulations were initially evaluated for particle size, PDI, zeta potential and entrapment efficiency to obtain the optimised formulation. Results: The optimised formulation TF 6 reported the particle size of 212.6±5.39 nm and entrapment efficiency of 91.02±0.57%; this was further characterised for FT-IR, DSC and scanning electron microscopy. The in vitro release of drug for the prepared formulations was performed for 24 h and the optimised formulation showed better-controlled drug release compared to other formulations. Conclusion: The pure Trandolapril solution was collated with the optimised formulation TF 6 and the result concluded that the formulation showed controlled drug release compared to pure drug. This study proves that Trandolapril SLNs can be prepared for increasing the release of drug for prolonged period.